


Prolytic and PRIMACYT co-operate for reduction of animal testing

Prolytic and PRIMACYT will be working together in the future, in order to provide pharmaceutical companies the possibility to investigate drugs using standardized human and animal hepatocytes. The use of human hepatocytes will lead to a reduction of animal experiments. Goal of the co-operation is to combine the cellular biology of hepatocyte cultures with the necessary analytics. The hepatocyte cultures will be incubated with the substance of interest at PRIMACYT and following the medium will be analyzed at Prolytic. Here the RIA and the HPLC-MS technology will be used.



With this co-operation we offer our customers the possibility to receive information about degradation of the drug by enzymes, drug mediation of enzyme induction or inhibition as well as possible interaction between different drugs. In conclusion, animal studies will be reduced to a minimum.

If you would like to have more information, please contact us. We will be happy to answer all of your questions.